Wednesday February 18, 01:25 PM
BRIEF-Arena says Merck to start phase 2 trial of niacin receptor agonist
Feb 18 (Reuters) - Arena Pharmaceuticals Inc (NASDAQ: ARNA - news) :
* Announces initiation by Merck KGaA (MKGAY.PK - news) of phase 2 clinical trial of niacin receptor agonist
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here)
COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters (TRI.TO - news) .
NNNN
|
|
|
Send Article by Email
Send Article by IM
Blog This with Y! 360
Printable View
